Failure to Meet Business Plans in New Business Fields
First written in FY2016. 13 of 28 entries say "Worsened", first in FY2021-Q1. Latest entry: 2026-10-08.
Rorze moved to the "Worse" side of this theme in 2021, 1 year before the typical company in this theme (2022).
The whole theme swung hardest in 2018: 14 of 79 companies on the "Worse" side.
7 other companies' latest entry also says "Worsened".
- 2026-10-08WorsenedEarnings
「In the life sciences business, net sales were ¥376 million, up 2.8% year on year, while the segment loss was ¥147 million, compared with a segment loss of ¥119 million in the same period of the previous year.」
The company disclosed that the life sciences business loss had widened in connection with the failure of a new business area to meet its business plan. - FY2026Added the risk of underperformance by acquired and investee companiesAnnual report
「If the performance of acquired and investee companies falls below their initial plans due to changes in the business environment or other factors, impairment of goodwill and intangible assets, additional investment and restructuring of management systems may be required.」
In addition to the risk of failing to meet new business plans, the disclosure explicitly states the possibility of impairment losses, additional investment and restructuring of management systems due to underperformance by acquired and investee companies. - FY2026-H1WorsenedAnnual report
「Revenue from the Life Science business was ¥366 million, up 9.5% year on year, and the segment loss was ¥119 million, compared with a segment loss of ¥52 million in the same period of the previous year.」
Despite higher revenue, the life sciences business, which has previously failed to meet its plans and incurred impairment losses, saw its segment loss widen from ¥52 million to ¥119 million. - FY2025-H1MitigatedAnnual report
「Revenue from the Life Science business was ¥334 million, up 118.7% year on year, and the segment loss was ¥52 million, compared with a segment loss of ¥97 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded higher revenue year on year, while its segment loss narrowed from ¥97 million to ¥52 million. - FY2025-Q1MitigatedAnnual report
「Revenue from the Life Science business was ¥152 million, up 52.1% year on year, and the segment loss was ¥40 million, compared with a segment loss of ¥62 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded higher revenue, while its segment loss narrowed year on year. - FY2024-Q3MitigatedAnnual report
「Revenue from the Life Science business was ¥300 million, up 21.0% year on year, and the segment loss was ¥115 million, compared with a segment loss of ¥116 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded a 21.0% year-on-year increase in revenue, while its segment loss narrowed slightly from ¥116 million to ¥115 million. - FY2024-Q2WorsenedAnnual report
「Revenue from the Life Science business was ¥152 million, down 17.6% year on year, and the segment loss was ¥97 million, compared with a segment loss of ¥88 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded lower revenue, while its segment loss widened year on year. - FY2024-Q1MitigatedAnnual report
「Revenue from the Life Science business was ¥100 million, up 123.5% year on year, and the segment loss was ¥62 million, compared with a segment loss of ¥76 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded higher revenue, while its segment loss narrowed year on year. - FY2023MitigatedAnnual report
「Revenue from the Life Science business was ¥1,186 million, up 57.6% from the previous fiscal year, and the segment profit was ¥89 million, up 727.7% from the previous fiscal year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded higher full-year revenue and turned profitable at the segment level. - FY2023-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥248 million, down 37.1% year on year, and the segment loss was ¥116 million, compared with a segment loss of ¥42 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded lower revenue, while its segment loss widened from ¥42 million in the same period of the previous year to ¥116 million. - FY2023-Q2WorsenedAnnual report
「Revenue from the Life Science business was ¥185 million, down 24.2% year on year, and the segment loss was ¥88 million, compared with a segment loss of ¥42 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded lower revenue, while its segment loss widened from ¥42 million in the same period of the previous year to ¥88 million. - FY2023-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥44 million, down 48.0% year on year, and the segment loss was ¥76 million, compared with a segment loss of ¥40 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, continued to record lower revenue and widening segment losses, indicating a deterioration in the risk of failing to meet the business plan. - FY2022-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥395 million, down 10.8% year on year, and the segment loss was ¥42 million, compared with a segment loss of ¥17 million in the same period of the previous year.」
The life sciences business, a new business, recorded lower revenue, and its segment loss widened from ¥17 million to ¥42 million. - FY2022-Q2WorsenedAnnual report
「In the Life Science business, the impact of COVID-19 continued. Revenue was ¥244 million, down 5.3% year on year, and the segment loss was ¥42 million, compared with a segment loss of ¥10 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded lower revenue as the impact of COVID-19 continued, with its segment loss widening from ¥10 million to ¥42 million. - FY2022-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥86 million, up 62.3% year on year, and the segment loss was ¥40 million, compared with a segment loss of ¥34 million in the same period of the previous year.」
Although the life sciences business recorded higher revenue, it remained in the red for the second consecutive period, with its segment loss widening from ¥34 million to ¥40 million. - FY2021WorsenedAnnual report
「In the Life Science business, shipments were delayed due to the impact of COVID-19. As a result, revenue was ¥686 million, down 16.1% from the previous fiscal year, and the segment loss was ¥0 million, compared with a segment profit of ¥51 million in the previous fiscal year.」
The life sciences business, a new business, recorded lower revenue due to shipment delays and turned from a profit in the previous fiscal year to a segment loss of ¥0 million. - FY2021-Q3WorsenedAnnual report
「Revenue from the Life Science business was ¥442 million, down 25.8% year on year, and the segment loss was ¥17 million, compared with a segment profit of ¥92 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its initial plan and incurred impairment losses, turned from a profit in the same period of the previous year to a loss, while revenue continued to decline. - FY2021-Q2WorsenedAnnual report
「In the Life Science business, shipments of equipment were delayed due to the impact of COVID-19. As a result, revenue was ¥258 million, down 21.0% year on year, and the segment loss was ¥10 million, compared with a segment profit of ¥63 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, recorded lower revenue year on year due to shipment delays and again turned from a profit to a loss. - FY2021-Q1WorsenedAnnual report
「Revenue from the Life Science business was ¥53 million, down 69.2% year on year, and the segment loss was ¥34 million, compared with a segment profit of ¥33 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its plans and incurred impairment losses, turned from a profit in the same period of the previous year to a loss, while the decline in revenue also widened. - FY2020MitigatedAnnual report
「Sales of automated cell culture equipment remained strong in Japan and overseas. As a result, revenue was ¥817 million, up 92.0% from the previous fiscal year, and the segment profit was ¥51 million, compared with a segment loss of ¥83 million in the previous fiscal year.」
Among the new businesses that have previously failed to meet their initial plans and incurred impairment losses, the life sciences business recorded higher revenue and turned profitable at the segment level. - FY2020-Q3MitigatedAnnual report
「Revenue from the Life Science business was ¥596 million, up 118.7% year on year, and the segment profit was ¥92 million, compared with a segment loss of ¥62 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its initial plan and incurred impairment losses, returned to a profit of ¥92 million from a loss in the same period of the previous year, while revenue increased 118.7%. - FY2020-Q2MitigatedAnnual report
「Revenue from the Life Science business was ¥327 million, up 102.7% year on year, and the segment profit was ¥63 million, compared with a segment loss of ¥43 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its initial plan and incurred impairment losses, returned to profit from a segment loss in the same period of the previous year, while revenue increased 102.7% year on year. - FY2020-Q1MitigatedAnnual report
「Revenue from the Life Science business was ¥172 million, up 43.5% year on year, and the segment profit was ¥33 million, compared with a segment loss of ¥2 million in the same period of the previous year.」
The life sciences business, which has previously failed to meet its initial plan and incurred impairment losses, improved from a segment loss in the same quarter of the previous year to a segment profit of ¥33 million in the first quarter under review. - FY2019MaterialisedAnnual report
「During the consolidated fiscal year under review, impairment indicators were identified because the profitability of operating assets at the consolidated subsidiaries JIKA JIKA CO.,LTD. and ローツェライフサイエンス株式会社 had declined significantly, so their carrying amounts were reduced to their recoverable amounts.」
Profitability in the new businesses continued to decline, and JIKA JIKA and ローツェライフサイエンス recorded a combined impairment loss of ¥35.914 million. The life sciences business also posted a segment loss of ¥83 million. - FY2018MaterialisedAnnual report
「In addition, because the performance of the business related to the goodwill attributable to ローツェライフサイエンス株式会社 has fallen significantly below the initial plan, the carrying amount of the asset group was reduced to its recoverable amount, and the reduction was recorded as an impairment loss under extraordinary losses. The recoverable amount used to measure the impairment loss was measured based on value in use. Because future cash flows are expected to be negative, value in use was assessed at zero.」
The life sciences business fell significantly below the initial plan, resulting in an impairment loss of ¥167.977 million on goodwill and other assets. An impairment loss of ¥312.718 million was also recognized for JIKA JIKA in the magnet business. - FY2016First statedAnnual report
「If the business plan is disrupted due to circumstances arising that differ from any forecasts, or for other reasons, this may affect the Group's business results and financial position.」
Risk of failure to meet plans associated with expansion into bio- and genome-related equipment and the magnet business.